Adverse events following immunization in Ontario's female school-based HPV program

Vaccine

Volumn 32, Issue 9, 2014, Pages 1061-1066

  Harris, Tara ^a   Williams, Dawn M ^a   Fediurek, Jill ^a   Scott, Tsui ^c   Deeks, Shelley L ^a,b  

^a PUBLIC HEALTH ONTARIO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ONTARIO MINISTRY OF HEALTH AND LONG TERM CARE   (Canada)

Author keywords

Adverse events; Human papillomavirus vaccine; Surveillance; Vaccine safety

Indexed keywords

ADVERSE EVENTS; HUMAN PAPILLOMAVIRUS VACCINE; SURVEILLANCE; VACCINE SAFETY;

ADOLESCENT; ADVERSE DRUG REACTION REPORTING SYSTEMS; CHILD; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; ONTARIO; PAPILLOMAVIRUS VACCINES; POPULATION SURVEILLANCE; PRODUCT SURVEILLANCE, POSTMARKETING; VACCINATION;

EID: 84895058746     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.01.004     Document Type: Article

References (37)

1. National Advisory Committee on Immunization (NACI) Statement on human papillomavirus vaccine. An advisory committee statement (ACS). Can Commun Dis Rep 2007, 33:1-31.
2. National Advisory Committee on Immunisation (NACI) Update on human papillomavirus (HPV) vaccines. An advisory committee statement (ACS). Can Commun Dis Rep 2012, 28. (ACS-1).
3. Government of Canada Publicly funded immunization programs in Canada-routine schedule for infants and children including special programs and catch-up programs (as of March 2013) [Internet] 2013, Government of Canada, Ottawa, ON, [updated March 2013; cited May 22, 2013]. Available from: http://www.phac-aspc.gc.ca/im/ptimprog-progimpt/table-1-eng.php.
4. ®. [Internet] 2013, Health Canada, Ottawa, ON, [updated May 7, 2013; cited May 22, 2013]. Available from: http://webprod5.hc-sc.gc.ca/noc-ac/index-eng.jsp.
5. ® human papillomavirus vaccine types 16 and 18 (recombinant, AS04 adjuvanted) [Internet] 2013, GlaxoSmithKline Inc., Mississauga, ON, [updated May 2, 2013; cited May 22, 2013]. Available from: http://www.gsk.ca/english/docs-pdf/product-monographs/Cervarix.pdf.
6. Prince Edward Island Cancer Treatment Centre HPV vaccine program expands to include boys [Internet] 2013, Prince Edward Island Cancer Treatment Centre, Charlottetown, PE, [updated April 18, 2013; cited June 3, 2013]. Available from: http://www.cancercentre.pe.ca/index.php3?number=news&dept=&newsnumber=8937&lang=E.
7. Statistics Canada Population estimates and projections. Population by year, by province and territory. [Internet]. 2012, Statistics Canada, Ottawa, ON, [updated Sept. 27, 2012; cited May 22, 2013]. Available from: http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/demo02a-eng.htm.
8. Block S.L., Brown D.R., Chatterjee A., Gold M.A., Sings H.L., Meibohm A., et al. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine. Pediatr Infect Dis J 2010, 29(2):95-101.
9. ® [Human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant], Merck's HPV vaccine, available to developing countries through UNICEF tender. [Internet] 2013, Merck & Co., Whitehouse Station, NJ, [updated May 9, 2013; cited May 22, 2013]. Available from: http://www.mercknewsroom.com/press-release/prescription-medicine-news/gardasil-human-papillomavirus-quadrivalent-types-6-11-16-an.
10. Global Advisory Committee on Vaccine Safety Report of meeting held 17-18 June 2009. Wkly Epidemiol Rec 2009, 84(32):325-332.
11. Slade B.A., Leidel L., Vellozzi C., Woo E.J., Hua W., Sutherland A., et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009, 302(7):750-757.
12. Gold M.S., McIntyre P. Human papillomavirus vaccine safety in Australia: experience to date and issues for surveillance. Sex Health 2010, 7(3):320-324.
13. ® (Human papillomavirus vaccine). Safety information. [Internet] 2010, Therapeutic Good Administration, Symonston, Australia, [updated June 24, 2010; cited May 22, 2013]. Available from: http://www.tga.gov.au/safety/alerts-medicine-gardasil-070624.htm.
14. Buttery J.P., Madin S., Crawford N.W., Elia S., La Vincente S., Hanieh S., et al. Mass psychogenic response to human papillomavirus vaccination. Med J Aust 2008, 189(5):261-262.
15. Gardasil® Package Insert-Gardasil®. [Internet] 2013, Merck & Co., Whitehouse Station, NJ, [updated March 2013; cited May 22, 2013]. Available from: http://www.merck.com/product/usa/pi_circulars/g/gardasil/gardasil_pi.pdf.
16. ®. Reminder to healthcare providers: 15m observation period needed after vaccination. [Internet] 2009, US Food & Drug Administration, Silver Spring, MD, [updated June 18, 2009; cited May 22, 2013]. Available from: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm165145.htm.
17. ® [quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine. [Internet] 2011, Merck Canada Inc., Kirkland, [updated July 14, 2011; cited May 22, 2013]. Available from: http://www.merck.ca/assets/en/pdf/products/GARDASIL-PM_E.pdf.
18. Nkanza J., Lafleche J., Anyoti H., Law B. Profile of adverse events following immunization with human papillomavirus vaccine and hepatitis B vaccine in females aged 9 to 26 years in Canada (July, 2006 to May, 2010). International Society for Pharmacovigilance: Annual Meeting 2010.
19. Klein N.P., Hansen J., Chao C., Velicer C., Emery M., Slezak J., et al. Safety of quadrivalent human papillomavirus vaccine administered routinely to females. Arch Pediatr Adolesc Med 2012, 1-9.
20. Gee J., Naleway A., Shui I., Baggs J., Yin R., Li R., et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the vaccine safety datalink. Vaccine 2011, 29(46):8279-8284.
21. Wilson S.E., Karas E., Crowcroft N.S., Bontovics E., Deeks S.L. Ontario's school-based HPV immunization program: school board assent and parental consent. Can J Public Health 2012, 103(1):34-39.
22. Wilson S., Harris T., Sethi P., Fediurek J., Deeks S. Vaccine coverage assessment for Ontario's school-based human papillomavirus vaccination program. 10th Canadian Immunization Conference 2012.
23. Health Protection and Promotion Act (HPPA) Health Protection and Promotion Act (HPPA). R.S.O. 1990, c. H.7, s. 38 (3); 1998, c. 18, Sched. G, s. 55 (4). [Internet] 2011, Ministry of Health & Long-Term Care, Toronto, ON, [updated Dec. 31, 2011; cited May 22, 2013]. Available from: http://www.e-laws.gov.on.ca/html/statutes/english/elaws_statutes_90h07_e.htm.
24. Infectious Diseases Protocol Infectious Diseases Protocol, 2009. Appendix B: Provincial case definitions for reportable diseases. Disease: Adverse events following immunization (AEFIs). [archived] 2009, Ministry of Health and Long-Term Care.
25. Council for International Organizations of Medical Sciences Definition and application of terms for vaccine pharmacovigilance. Report of CIOMS/WHO Working Group on Vaccine Pharmacovigilance [Internet] 2012, Council for International Organizations of Medical Sciences, Geneva, [updated 2012; cited May 22, 2013]. Available from: http://www.cioms.ch/index.php/publications/available-publications?task=view&id=40&catid=54.
26. Ruggeberg J.U., Gold M.S., Bayas J.M., Blum M.D., Bonhoeffer J., Friedlander S., et al. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 2007, 25(31):5675-5684.
27. Ogilvie G., Anderson M., Marra F., McNeil S., Pielak K., Dawar M., et al. A population-based evaluation of a publicly funded, school-based HPV vaccine program in British Columbia, Canada: parental factors associated with HPV vaccine receipt. PLoS Med 2010, 7(5):e1000270.
28. Haesebaert J, Lutringer-Magnin D, Kalecinski J, Barone G, Jacquard A, Regnier V. French women's knowledge of and attitudes towards cervical cancer prevention and the acceptability of HPV vaccination among those with 14-18 year old daughters: a quantitative-qualitative study. BMC Public Health (1):1034.
29. Constantine N.A., Jerman P. Acceptance of human papillomavirus vaccination among Californian parents of daughters: a representative statewide analysis. J Adolesc Health 2007, 40(2):108-115.
30. Dahlstrom L.A., Tran T.N., Lundholm C., Young C., Sundstrom K., Sparen P. Attitudes to HPV vaccination among parents of children aged 12-15 years-a population-based survey in Sweden. Int J Cancer 2010, 126(2):500-507.
31. Weber J.C. Epidemiology of adverse reactions to non-steroidal anti-inflammatory drugs. Adv Inflammation Res 1984, 6:1-7.
32. Zhou W., Pool V., Iskander J.K., English-Bullard R., Ball R., Wise R.P., et al. Surveillance for safety after immunization: vaccine adverse event reporting system (VAERS)-United States, 1991-2001. MMWR Surveill Summ 2003, 52(1):1-24.
33. National Advisory Committee on Immunisation (NACI) Vaccine safety and adverse events following immunization. Anaphylaxis: initial management in non-hospital settings. Canadian immunization guide 2006, 80. Public Health Agency of Canada (PHAC), Ottawa, ON. 7th ed.
34. Varricchio F., Iskander J., Destefano F., Ball R., Pless R., Braun M.M., et al. Understanding vaccine safety information from the vaccine adverse event reporting system. Pediatr Infect Dis J 2004, 23(4):287-294.
35. Infectious Diseases Protocol Infectious Diseases Protocol, 2013. Appendix B: provincial case definitions for reportable diseases. disease: adverse events following immunization (AEFIs) [Internet] 2013, Ministry of Health & Long-Term Care, Toronto, ON, [updated Jan.1, 2013; cited May 22, 2013]. Available from: http://www.health.gov.on.ca/en/pro/programs/publichealth/oph_standards/docs/aefi_cd.pdf.
36. Siegrist C.A., Lewis E.M., Eskola J., Evans S.J., Black S.B. Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions. Pediatr Infect Dis J 2007, 26(11):979-984.
37. Wilson S.E., Harris T., Sethi P., Fediurek J., Macdonald L., Deeks S.L. Coverage from Ontario, Canada's school-based HPV vaccine program: the first three years. Vaccine 2013, 31(5):757-762.